Doximity
DOCS
$20.59
-1.39%
Doximity, Inc. operates a digital platform for U.S. healthcare professionals, providing tools for networking, medical news, career management, and telehealth. The company has established itself as a dominant platform and network effect leader within the medical community, connecting physicians and serving pharmaceutical and health system clients through its Marketing, Hiring, and Workflow Solutions. The current investor narrative is dominated by a sharp reassessment of its growth trajectory following a disappointing earnings report in May 2026, which revealed a significant slowdown in future revenue growth expectations and triggered a massive stock decline, forcing a debate between its strong market position and near-term fundamental headwinds.…
DOCS
Doximity
$20.59
Related headlines
Investment Opinion: Should I buy DOCS Today?
Rating: Hold. The core thesis is that while the catastrophic sell-off has created a more compelling valuation, the severe growth deceleration and broken technical picture necessitate a cautious stance until evidence of stabilization emerges.
Supporting Evidence: The stock trades at a forward P/E of 13.1x, which is reasonable for a profitable company, but this multiple is justified by the sharp slowdown in revenue growth to 9.76% YoY. Profitability remains strong with an 89.89% gross margin and $311.55M in TTM FCF, and the balance sheet is rock-solid with a 0.011 debt-to-equity ratio. However, the stock is still down 65.44% over the past year and trades just 21.8% above its 52-week low, reflecting deep-seated negative momentum that outweighs the value argument for now.
Risks & Conditions: The two biggest risks are 1) further growth deceleration below the current ~10% rate, and 2) continued operating margin compression eroding the bottom line. This Hold rating would upgrade to a Buy if the company demonstrates a clear re-acceleration of revenue growth back above 15% YoY for two consecutive quarters, or if the forward P/E compresses further to the single digits (e.g., below 10x) without a deterioration in fundamentals. It would downgrade to a Sell if revenue growth turns negative or if operating margins fall below 30%. Relative to its own history, the stock is undervalued, but relative to its new growth profile, it appears fairly valued to slightly overvalued until growth stabilizes.
Sign up to view all
DOCS 12-Month Price Forecast
The investment case for DOCS is in transition from a high-growth SaaS story to a profitable, slower-growth cash generator. The base case (55% probability) of range-bound trading is most likely, as the market digests the new growth reality and awaits confirmation of stability. The substantial cash flow and lack of debt limit near-term existential risk, but the broken price trend and high beta warrant caution. The stance would upgrade to bullish on evidence of growth re-acceleration above 12% for two consecutive quarters, supported by stable margins. It would turn bearish if revenue growth dips below 5% or if the stock decisively breaks below the $17 support level on high volume.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Doximity's 12-month outlook, with a consensus price target around $26.77 and implied upside of +30.0% versus the current price.
Average Target
$26.77
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$16 - $27
Analyst target range
Analyst coverage for Doximity appears limited, with only 2 analysts providing estimates for future EPS and revenue, though the institutional ratings data shows activity from several major firms. The consensus sentiment, as evidenced by recent ratings actions, is mixed but leaning cautiously optimistic; since the February 2026 earnings, firms including Piper Sandler, Barclays, and Morgan Stanley have maintained Overweight ratings, while JP Morgan upgraded from Underweight to Neutral, and Canaccord Genuity upgraded from Hold to Buy. The average revenue estimate for the forward period is $810 million, with a range from $795.4 million to $828.2 million. The lack of a published consensus price target in the provided data suggests high uncertainty, but the recent rating actions following the disappointing earnings indicate analysts are grappling with the new growth reality—some see the sell-off as overdone given the company's profitability and market position, while others remain neutral awaiting clearer signs of a re-acceleration. The wide dispersion in forward revenue estimates and the mix of rating actions signal significant debate and a lack of strong conviction on the near-term path, which is typical following a fundamental inflection point.
Bulls vs Bears: DOCS Investment Factors
The bear case currently holds stronger evidence, anchored by the severe and sudden deceleration in revenue growth to 9.76% YoY—the single most important fundamental metric for a former high-growth SaaS stock. This has triggered a justified valuation derating and a catastrophic technical breakdown. However, the bull case is supported by an extreme valuation compression to a 13.1x forward P/E and a pristine, cash-generative balance sheet, suggesting the sell-off may have been overdone. The central tension in the investment debate is whether Doximity's dominant network and high profitability can support a stable, mid-single-digit growth business worthy of its current valuation, or if the growth slowdown is structural and will lead to further multiple contraction and earnings disappointment.
Bullish
- Extreme Valuation Compression: The stock trades at a forward P/E of 13.1x, a significant discount to its trailing P/E of 22.2x and a collapse from a P/S ratio over 44x in late 2025 to just 6.76x. This suggests the market has priced in severe pessimism, creating a potential value opportunity if the business stabilizes.
- Exceptional Profitability & Cash Flow: The company maintains a robust gross margin of 89.89% and generated $311.55M in TTM free cash flow. With a debt-to-equity ratio of 0.011 and a current ratio of 6.09, it has a fortress balance sheet with ample liquidity to navigate headwinds.
- Dominant Network Effect Platform: Doximity operates the leading digital platform for U.S. healthcare professionals, creating a significant competitive moat. This entrenched position provides a durable revenue base from pharmaceutical and health system clients, even as growth slows.
- Analyst Upgrades Post-Crash: Following the May 2026 crash, analysts from JP Morgan and Canaccord Genuity upgraded their ratings (to Neutral and Buy, respectively), while others maintained Overweight stances. This suggests some professional investors view the sell-off as overdone relative to the company's fundamentals.
Bearish
- Severe Growth Deceleration: The most recent quarterly revenue growth decelerated sharply to 9.76% YoY, down from much higher rates in prior comparable periods. This fundamental slowdown is the core driver of the stock's 65% annual decline and calls into question its former high-growth premium.
- Operating Margin Compression: The Q3 2026 operating margin of 38.85% has contracted from 47.40% in the year-ago quarter. This indicates that despite high gross margins, profitability is under pressure, potentially limiting earnings growth even if revenue stabilizes.
- Catastrophic Price & Momentum Breakdown: The stock is down 72.7% from its 52-week high, with a max drawdown of -76.03%. It remains in a severe downtrend, having broken all major support levels, and faces immense overhead resistance, suggesting a sustained recovery will be difficult.
- High Volatility & Market Sensitivity: With a beta of 1.29, DOCS is 29% more volatile than the market. This heightened sensitivity has amplified its downside during the growth stock sell-off and increases risk for investors, as evidenced by its -84.58% 1-year relative strength versus the S&P 500.
DOCS Technical Analysis
The prevailing price trend is a severe and sustained downtrend, with the stock down 65.44% over the past year and 52.21% over the last six months. The current price of $20.88 sits just 21.8% above its 52-week low of $17.15, trading near the absolute bottom of its 52-week range; this positioning indicates the stock is in deep value territory but also suggests a complete breakdown of prior support levels and persistent negative momentum. Recent short-term momentum shows a modest 3.06% gain over the past month, which is a positive divergence from the broader market's 2.86% decline, yet this minor bounce follows a catastrophic 11.86% decline over the prior three months and a massive drop from over $44 in late December to below $19 in May. This divergence suggests potential for a technical oversold bounce, but the stock remains 72.7% below its 52-week high of $76.51, indicating any recovery faces immense overhead resistance. Key technical levels are clearly defined, with immediate resistance likely forming around the $25-$27 area where the stock consolidated after its initial February/March crash, and major support at the 52-week low of $17.15. A beta of 1.29 indicates the stock is approximately 29% more volatile than the broader market, which has contributed to its dramatic drawdown of -76.03% and underscores the heightened risk profile for investors considering a position during this period of extreme weakness.
Beta
1.29
1.29x market volatility
Max Drawdown
-76.0%
Largest decline past year
52-Week Range
$17-$77
Price range past year
Annual Return
-66.3%
Cumulative gain past year
| Period | DOCS Return | S&P 500 |
|---|---|---|
| 1m | -3.8% | -2.0% |
| 3m | -11.6% | +13.9% |
| 6m | -53.5% | +8.7% |
| 1y | -66.3% | +20.5% |
| ytd | -52.4% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOCS Fundamental Analysis
The company's revenue trajectory has decelerated significantly, with the most recent quarterly revenue of $185.05 million representing a year-over-year growth of only 9.76%, a sharp slowdown from the stronger growth rates seen in prior comparable periods. This deceleration is the core issue driving the stock's re-rating, as the subscription segment, which constitutes the vast majority ($175.38 million) of total revenue, appears to be maturing faster than anticipated. Profitability remains robust on a reported basis, with the latest quarter showing net income of $61.56 million and an exceptionally high gross margin of 89.89%, demonstrating the asset-light, high-margin nature of the platform. However, operating income of $71.90 million and an operating margin of 38.85% for Q3 2026 show some compression from the year-ago period's operating margin of 47.40%, indicating that while still highly profitable, margin expansion may have peaked. The balance sheet and cash flow position remain exceptionally strong, with a debt-to-equity ratio of just 0.011 indicating a virtually debt-free capital structure, and a current ratio of 6.09 signaling ample liquidity. The company generated $311.55 million in trailing twelve-month free cash flow, representing a substantial FCF yield at the current market cap, and an ROE of 20.62% demonstrates efficient use of equity, though this is down from higher historical levels, reflecting the impact of the stock price decline on the equity base.
Quarterly Revenue
$185053000.0B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.89%
Latest Quarter
Free Cash Flow
$311547000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOCS Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E stands at 22.2x, while the forward P/E is significantly lower at 13.1x, indicating the market expects a substantial earnings recovery or that current earnings are depressed relative to forward estimates. Compared to industry averages, which are not provided in the dataset, a direct sector comparison is not possible; however, a trailing P/E of 22.2x for a company with decelerating high-single-digit revenue growth appears rich without context, though the forward multiple suggests the market is pricing in a normalization. Historically, the stock's valuation has collapsed from its peak; for instance, its Price-to-Sales (P/S) ratio has fallen from over 44x in late 2025 to 6.76x currently, and its P/E has dropped from over 58x in September 2025 to the current 22.2x. This places the stock near the bottom of its own historical valuation range, suggesting the market has already priced in significant pessimism regarding its growth prospects, potentially creating a value opportunity if the business stabilizes.
PE
22.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 27x~112x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the sustainability of Doximity's business model following its growth deceleration. Revenue growth has slowed sharply to 9.76% YoY, and operating margins have compressed from 47.4% to 38.85% year-over-year, indicating potential earnings pressure ahead. While the balance sheet is strong with minimal debt, the company's valuation (forward P/E of 13.1x) now hinges on its ability to stabilize growth and defend margins; further deterioration could trigger another leg down. The subscription-heavy revenue model, while high-margin, may face saturation within its core U.S. physician market.
Market & Competitive Risks are elevated due to the stock's high volatility (beta of 1.29) and its dramatic repricing from growth to value. Trading at a P/S of 6.76x, down from over 44x, the stock remains vulnerable to sector-wide de-rating if interest rates stay higher for longer, compressing multiples for all but the fastest growers. Competitive disruption from broader healthcare IT platforms or shifts in pharmaceutical marketing budgets pose external threats, though its network effect provides some defense. The recent news of a 'disappointing earnings report' in May 2026 highlights how sensitive the stock is to growth guidance misses.
Worst-Case Scenario involves a failure to stabilize growth, leading to a further decline in revenue growth to low single digits and continued margin compression. This could result in earnings misses, analyst downgrades, and a loss of investor confidence, driving the stock to retest and break below its 52-week low of $17.15. Given the stock's high beta and demonstrated capacity for severe drawdowns (-76% max), a realistic downside from the current price of $20.88 could be -18% to the 52-week low, with potential for further declines into the low teens if the business fundamentals deteriorate meaningfully, representing a total loss of 30-40% from current levels.
FAQ
The primary risk is fundamental: further deceleration of revenue growth below the current 9.76% rate, which would challenge the valuation floor. Second is operational margin compression, as seen in the YoY decline from 47.4% to 38.85%, which could pressure earnings even if revenue stabilizes. Third is market-related: with a beta of 1.29, DOCS is highly sensitive to market downturns and sector rotation away from slower-growing tech stocks. Fourth is technical/sentiment risk: the stock is down 72.7% from its high and faces immense overhead resistance; renewed selling could easily push it to new lows, triggering stop-losses and further declines.
The 12-month outlook is defined by three scenarios with associated probabilities. The base case (55% probability) sees the stock trading between $22 and $28 as growth stabilizes in the 8-12% range. The bull case (25% probability) projects a rally to $32-$38 on evidence of re-accelerating growth and multiple expansion. The bear case (20% probability) warns of a drop to $15-$19 if growth deteriorates further and the stock breaks key support. The base case is most likely, anchored by the expectation that the company's strong profitability and cash flow will prevent a more severe collapse, but insufficient growth will cap meaningful upside in the near term.
DOCS appears fairly valued to slightly undervalued relative to its current fundamentals but remains overvalued relative to its former high-growth premium. The forward P/E of 13.1x is reasonable for a profitable company with an 89.89% gross margin. However, the trailing P/E of 22.2x and the dramatic collapse in the P/S ratio from over 44x to 6.76x show the market has aggressively re-rated the stock. The valuation implies the market expects mid-to-high single-digit growth to persist. Compared to its own history, it is deeply undervalued; compared to its new growth profile, it is fairly priced, leaving little margin of safety without evidence of stabilization.
DOCS presents a high-risk, high-potential-reward opportunity that is not suitable for all investors. For value-oriented investors with a long-term horizon and high risk tolerance, the current forward P/E of 13.1x and strong balance sheet may be attractive following the 65% decline. However, the severe growth deceleration to 9.76% YoY and broken technical picture mean it is not a 'good buy' for growth investors or those with low volatility tolerance. The stock could be a good buy for contrarians if they believe the growth slowdown is temporary and the network effect is durable, but they must be prepared for further volatility given its 1.29 beta.
DOCS is unsuitable for short-term trading due to its high volatility (beta 1.29) and severely damaged technical trend, which lacks clear directional momentum. For long-term investors, the stock could be appropriate if one believes in the durability of its healthcare professional network and its ability to eventually re-accelerate growth, but this requires a multi-year horizon to play out. The lack of a dividend means total return is dependent solely on price appreciation. A minimum holding period of 2-3 years is suggested to allow for the company's narrative to transition and for potential operational improvements to materialize, though investors must be prepared for significant volatility along the way.